Winters-Stone Kerri M, Horak Fay, Jacobs Peter G, Trubowitz Phoebe, Dieckmann Nathan F, Stoyles Sydnee, Faithfull Sara
Kerri M. Winters-Stone, Fay Horak, Peter G. Jacobs, Phoebe Trubowitz, Nathan F. Dieckmann, and Sydnee Stoyles, Oregon Health & Science University, Portland, OR; and Sara Faithfull, University of Surrey, Guildford, Surrey, United Kingdom.
J Clin Oncol. 2017 Aug 10;35(23):2604-2612. doi: 10.1200/JCO.2016.71.3552. Epub 2017 Jun 6.
Purpose Chemotherapy-induced peripheral neuropathy (CIPN) may persist after treatment ends and may lead to functional decline and falls. This study compared objective and self-report measures of physical function, gait patterns, and falls between women cancer survivors with and without symptoms of CIPN to identify targets for functional rehabilitation. Methods A secondary data analysis of 512 women cancer survivors (age, 62 ± 6 years; time since diagnosis, 5.8 ± 4.1 years) categorized and compared women self-reporting symptoms of CIPN (CIPN+) with asymptomatic women (CIPN-) on the following: maximal leg strength, timed chair stand, physical function battery, gait characteristics (speed; step number, rate, and length; base of support), self-report physical function and disability, and falls in the past year. Results After an average of 6 years after treatment, 47% of women still reported symptoms of CIPN. CIPN+ had significantly worse self-report and objectively measured function than did CIPN-, with the exception of maximal leg strength and base of support during a usual walk. Gait was slower among CIPN+, with those women taking significantly more, but slower and shorter, steps than did CIPN- (all P < .05). CIPN+ reported significantly more disability and 1.8 times the risk of falls compared with CIPN- ( P < .0001). Increasing symptom severity was linearly associated with worsening function, increasing disability, and higher fall risk (all P < .05). Conclusion This work makes a significant contribution toward understanding the functional impact of CIPN symptoms on cancer survivors. Remarkably, 47% of women in our sample had CIPN symptoms many years after treatment, together with worse function, greater disability, and more falls. CIPN must be assessed earlier in the clinical pathway, and strategies to limit symptom progression and to improve function must be included in clinical and survivorship care plans.
目的 化疗引起的周围神经病变(CIPN)在治疗结束后可能持续存在,并可能导致功能衰退和跌倒。本研究比较了有和没有CIPN症状的女性癌症幸存者在身体功能、步态模式和跌倒方面的客观测量指标与自我报告指标,以确定功能康复的目标。方法 对512名女性癌症幸存者(年龄62±6岁;确诊后时间5.8±4.1年)进行二次数据分析,将自我报告有CIPN症状的女性(CIPN+)与无症状女性(CIPN-)在以下方面进行分类和比较:最大腿部力量、定时起立试验、身体功能测试、步态特征(速度;步数、步频和步长;支撑面)、自我报告的身体功能和残疾情况以及过去一年的跌倒情况。结果 治疗平均6年后,47%的女性仍报告有CIPN症状。CIPN+的自我报告功能和客观测量功能明显比CIPN-差,但在最大腿部力量和正常行走时的支撑面方面除外。CIPN+的步态较慢,这些女性的步数明显更多,但步速更慢、步长更短,与CIPN-相比差异均有统计学意义(均P<.05)。与CIPN-相比,CIPN+报告的残疾明显更多,跌倒风险是CIPN-的1.8倍(P<.0001)。症状严重程度增加与功能恶化、残疾增加和跌倒风险升高呈线性相关(均P<.05)。结论 本研究对于理解CIPN症状对癌症幸存者的功能影响做出了重要贡献。值得注意的是,我们样本中的47%女性在治疗多年后仍有CIPN症状,同时伴有更差的功能、更大的残疾和更多的跌倒。必须在临床路径中更早地评估CIPN,并且临床和生存护理计划中必须纳入限制症状进展和改善功能的策略。